Abhay R. Singh

Abhay R. Singh

Hematology | Oncology
9500 Euclid Avenue
Cleveland, OH 44195

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 51 publications

In Reply: The intersection of CHIP and HIV: Implications for cardiovascular risk stratification.

In Reply: The intersection of CHIP and HIV: Implications for cardiovascular risk stratification.

Journal: Cleveland Clinic journal of medicine
Published: August 03, 2026

Reply to "Does disease ontogeny matter more than JAK2 mutation status in acute myeloid leukemia?"

Reply to "Does disease ontogeny matter more than JAK2 mutation status in acute myeloid leukemia?"

Journal: Cancer
Published: July 22, 2026

The Prognostic Utility of Normal Karyotype Fraction in Acute Myeloid Leukemia.

The Prognostic Utility of Normal Karyotype Fraction in Acute Myeloid Leukemia.

Journal: Clinical lymphoma, myeloma & leukemia
Published: June 11, 2026

Clonal hematopoiesis of indeterminate potential and heart disease: What every internist needs to know.

Clonal hematopoiesis of indeterminate potential and heart disease: What every internist needs to know.

Journal: Cleveland Clinic journal of medicine
Published: May 01, 2026

HSR26-258: Patient-Level Impact of the 2023 Platinum Chemotherapy Shortage on Access of Treatment in Lung Cancer.

HSR26-258: Patient-Level Impact of the 2023 Platinum Chemotherapy Shortage on Access of Treatment in Lung Cancer.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 16, 2026

HSR26-258: Patient-Level Impact of the 2023 Platinum Chemotherapy Shortage on Access of Treatment in Lung Cancer.

HSR26-258: Patient-Level Impact of the 2023 Platinum Chemotherapy Shortage on Access of Treatment in Lung Cancer.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026

Longitudinal analysis of tyrosine kinase inhibitor therapy outcomes and BCR-ABL1 transcript decline velocity in chronic myeloid leukemia: A 16-year real-world study.

Longitudinal analysis of tyrosine kinase inhibitor therapy outcomes and BCR-ABL1 transcript decline velocity in chronic myeloid leukemia: A 16-year real-world study.

Journal: Cancer
Published: March 27, 2026

Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

Journal: Current oncology reports
Published: March 01, 2026

Cytokine receptor and JAK/STAT pathway mutations in acute myeloid leukemia: Prevalence and clinical impact.

Cytokine receptor and JAK/STAT pathway mutations in acute myeloid leukemia: Prevalence and clinical impact.

Journal: Cancer
Published: February 08, 2026

Risk Factors beyond Chemotherapy Exposure for Secondary Myeloid Neoplasms after Hematologic Cancers: A SEER-Based Study.

Risk Factors beyond Chemotherapy Exposure for Secondary Myeloid Neoplasms after Hematologic Cancers: A SEER-Based Study.

Journal: Cancer research communications
Published: June 30, 2025

Comparative Outcomes of Intensive Chemotherapy Versus Venetoclax Plus Hypomethylating Agents in Acute Myeloid Leukemia Patients Aged 60-75 Years: A Propensity Score-Adjusted Cohort Study.

Comparative Outcomes of Intensive Chemotherapy Versus Venetoclax Plus Hypomethylating Agents in Acute Myeloid Leukemia Patients Aged 60-75 Years: A Propensity Score-Adjusted Cohort Study.

Journal: Clinical lymphoma, myeloma & leukemia
Published: June 21, 2025

Unravelling the potential of small molecule tumor necrosis factor-α (TNF) inhibitors: A comprehensive review.

Unravelling the potential of small molecule tumor necrosis factor-α (TNF) inhibitors: A comprehensive review.

Journal: Bioorganic & medicinal chemistry
Published: June 01, 2025
Showing 1-12 of 51

Last Updated: 09/26/2026